Comera Life Sciences Holdings, Inc. (CMRA)
- Previous Close
0.0307 - Open
0.0292 - Bid --
- Ask --
- Day's Range
0.0292 - 0.0292 - 52 Week Range
0.0210 - 0.7390 - Volume
399 - Avg. Volume
11,204 - Market Cap (intraday)
899,080 - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
comeralifesciences.comRecent News: CMRA
Performance Overview: CMRA
Trailing total returns as of 5/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMRA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMRA
Valuation Measures
Market Cap
899.08k
Enterprise Value
-697.19k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.57
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-119.35%
Return on Equity (ttm)
-1,629.02%
Revenue (ttm)
1M
Net Income Avi to Common (ttm)
-9.35M
Diluted EPS (ttm)
-0.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
1.77M
Total Debt/Equity (mrq)
549.04%
Levered Free Cash Flow (ttm)
-2.99M